文献速递乳腺癌

低危乳腺浸润癌加速部分乳腺照射与全乳照射的美容效果与副作用:随机III期IRMA试验

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
PubMed 文献 · J Clin Oncol · 2023-01-09

IRMA随机III期试验在35个中心纳入3309例49岁以上I-IIA期保乳术后乳腺癌患者,1:1随机接受全乳照射或外照射加速部分乳腺照射(38.5 Gy/10次,每日两次)。中位随访5.6年,APBI组3年和5年不良美容结局及晚期软组织、骨grade≥3毒性均高于WBI组,皮肤和肺晚期毒性无显著差异。

要点

  • APBI组3年不良美容结局12.7% vs WBI组9.2%(P=.009),5年14% vs 9.8%(P=.012)。
  • APBI组晚期软组织grade≥3毒性2.8% vs WBI组1%(P<.0001)。
  • APBI组晚期骨grade≥3毒性1.1% vs WBI组0%(P<.0001)。

核心结论

  • 外照射APBI每日两次方案与晚期中度软组织和骨毒性增加相关,5年患者报告的美容结局较WBI略有下降,但总体毒性在可接受范围内。

研究设计与样本

  • 随机III期试验在35个中心开展,入组I-IIA期保乳术后、年龄≥49岁乳腺癌患者,1:1随机接受WBI或外照射APBI(38.5 Gy/10次,每日两次)。
  • 2007年3月至2019年3月共随机3309例(WBI 1657例,APBI 1652例),意向治疗人群3225例(WBI 1623例,APBI 1602例)。
  • 主要终点为同侧乳腺肿瘤复发,本文报告次要结局美容效果和正常组织毒性,采用RTOG/EORTC放射损伤评分标准,按意向治疗和实际治疗两种方式分析。

主要发现

  • 中位随访5.6年(四分位距4.0-8.4年),APBI组不良美容结局3年为12.7% vs WBI组9.2%(P=.009),5年为14% vs 9.8%(P=.012)。
  • 晚期软组织毒性grade≥3为APBI组2.8% vs WBI组1%(P<.0001),APBI组更高。
  • 晚期骨毒性grade≥3为APBI组1.1% vs WBI组0%(P<.0001),APBI组更高。
  • 晚期皮肤和肺毒性两组无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The results in terms of side effects vary among the published accelerated partial-breast irradiation (APBI) studies. Here, we report the 5-year results for cosmetic outcomes and toxicity of the IRMA trial. METHODS: We ran this randomized phase III trial in 35 centers. Women with stage I-IIA breast cancer treated with breast-conserving surgery, age ≥ 49 years, were randomly assigned 1:1 to receive either whole-breast irradiation (WBI) or external beam radiation therapy APBI (38.5 Gy/10 fraction twice daily). Patients and investigators were not masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence. We hereby present the analysis of the secondary outcomes, cosmesis, and normal tissue toxicity. All side effects were graded with the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Radiation Morbidity Scoring Schema. Analysis was performed with both intention-to-treat and as-treated approaches. RESULTS: Between March 2007 and March 2019, 3,309 patients were randomly assigned to 1,657 WBI and 1,652 APBI; 3,225 patients comprised the intention-to-treat population (1,623 WBI and 1,602 APBI). At a median follow-up of 5.6 (interquartile range, 4.0-8.4) years, adverse cosmesis in the APBI patients was higher than that in the WBI patients at 3 years (12.7% v 9.2%; P = .009) and at 5 years (14% v 9.8%; P = .012). Late soft tissue toxicity (grade ≥ 3: 2.8% APBI v 1% WBI, P < .0001) and late bone toxicity (grade ≥ 3: 1.1% APBI v 0% WBI, P < .0001) were significantly higher in the APBI arm. There were no significant differences in late skin and lung toxicities. CONCLUSION: External beam radiation therapy-APBI with a twice-daily IRMA schedule was associated with increased rates of late moderate soft tissue and bone toxicities, with a slight decrease in patient-reported cosmetic outcomes at 5 years when compared with WBI, although overall toxicity was in an acceptable range.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Meduri B, Baldissera A, Iotti C, et al. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial. J Clin Oncol. 2023. PMID: 36623246. doi:10.1200/JCO.22.01485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。